This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Short Report
Povidone-iodine demonstrates rapid in-vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease
Maren Eggers
Labor Prof. Dr. G. Enders MVZ GbR, Rosenbergstraße 85, 70193, Stuttgart, Germany
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version here.
Introduction: Within six months of its emergence, SARS‑CoV‑2 has infected 5.5 million people worldwide, causing >345,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in-vitro virucidal activity of topical and oral povidone-iodine (PVP‑I) products against SARS‑CoV‑2.
Methods: Suspension assays were used to assess the virucidal activity of PVP‑I against SARS‑CoV‑2. Products were tested at a contact time of 30 seconds for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as TCID50/mL.
Results: All four products (antiseptic solution [PVP-I 10%], skin cleanser [PVP-I 7.5%], gargle and mouth wash [PVP-I 1%] and throat spray [PVP-I 0.45%] achieved ≥99.99% virucidal activity against SARS-CoV-2, corresponding to ≥4 log10 reduction of virus titre, within 30 seconds of contact.
Conclusion: This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination and could be readily integrated into COVID-19 infection control measures in hospital and community settings.
Keywords
Anti-infective agents, Povidone-iodine, Viruses, Respiratory tract infections, COVID-19, SARS-CoV-2
This is a list of supplementary files associated with this preprint. Click to download.
ibrahimewais
commented on 28 June, 2020
nice
Mostafa khafagi
commented on 04 July, 2020
Is it difficult to know the effect of this antisetic nasal drops and mouth wash on the prevention of covid 19 infection??
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 17 Jun, 2020
Published
On 08 Jul, 2020
Community comments: 2
Community comments: 1
Metrics
Comments: 2
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This is a preprint. It has not completed peer review.
Short Report
Povidone-iodine demonstrates rapid in-vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease
Maren Eggers
Labor Prof. Dr. G. Enders MVZ GbR, Rosenbergstraße 85, 70193, Stuttgart, Germany
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 2
Posted 17 Jun, 2020
Published
On 08 Jul, 2020
Community comments: 2
Community comments: 1
Metrics
Comments: 2
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version here.
Introduction: Within six months of its emergence, SARS‑CoV‑2 has infected 5.5 million people worldwide, causing >345,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in-vitro virucidal activity of topical and oral povidone-iodine (PVP‑I) products against SARS‑CoV‑2.
Methods: Suspension assays were used to assess the virucidal activity of PVP‑I against SARS‑CoV‑2. Products were tested at a contact time of 30 seconds for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as TCID50/mL.
Results: All four products (antiseptic solution [PVP-I 10%], skin cleanser [PVP-I 7.5%], gargle and mouth wash [PVP-I 1%] and throat spray [PVP-I 0.45%] achieved ≥99.99% virucidal activity against SARS-CoV-2, corresponding to ≥4 log10 reduction of virus titre, within 30 seconds of contact.
Conclusion: This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination and could be readily integrated into COVID-19 infection control measures in hospital and community settings.
ibrahimewais
commented on 28 June, 2020
nice
Mostafa khafagi
commented on 04 July, 2020
Is it difficult to know the effect of this antisetic nasal drops and mouth wash on the prevention of covid 19 infection??